SR9009

SR9009

Identifiers
IUPAC name ethyl-3-(((4-chlorobenzyl)((5-nitrothiophen-2-yl)methyl)amino)methyl)pyrrolidine-1-carboxylate
CAS Number	1379686-30-2
PubChem CID	57394020
ChemSpider	28487410
ChEMBL	CHEMBL1961796
Chemical and physical data
Formula	C20H24ClN3O4S
Molar mass	437.94026
3D model (JSmol)	Interactive image
SMILES CCOC(=O)N1CCC(C1)CN(CC2=CC=C(C=C2)Cl)CC3=CC=C(S3)[N+](=O)[O-]
InChI InChI=1S/C20H24ClN3O4S/c1-2-28-20(25)23-10-9-16(13-23)12-22(11-15-3-5-17 (21)6-4-15)14-18-7-8-19(29-18)24(26)27/h3-8,16H,2,9-14H2,1H3 Key:MMJJNHOIVCGAAP-UHFFFAOYSA-N

SR9009 also known as Stenabolic is a research drug that was developed by Professor Thomas Burris of the Scripps Research Institute as an agonist of Rev-ErbA (i.e., increases the constitutive repression of genes regulated by Rev-ErbA) with a half-maximum inhibitory concentration (IC₅₀) = 670 nM for Rev-ErbAα and IC₅₀ = 800 nM for Rev-ErbAβ.

Activation of Rev-erb-α by in mice SR9009 increases exercise capacity in mice by increasing in skeletal muscle.